Sharon Durfy

Sharon Durfy

Auto-generated profile, based on publicly available information

Sharon Durfy

Department of Neurological Surgery, University of Washington, Seattle, WA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2024 in World Neurosurgery
Verified
Journal Article
Closed access
DBDavid Bonda
David Bonda
KKKatherine A. Kelly
Katherine A. Kelly
SBScott Boop
Scott Boop
AFAbdullah H Feroze
Abdullah H Feroze
SRStephanie C. Randle
Stephanie C. Randle
JHJason S. Hauptman
Jason S. Hauptman

1 January 2020 in Investigative and Clinical Urology
Verified
Journal Article
Open access
EBElliot K. Blau
Elliot K. Blau
SASarah A. Adelstein
Sarah A. Adelstein
KAKatherine A. Amin
Katherine A. Amin
SDSharon J. Durfy
Sharon J. Durfy
ALAlvaro Lucioni
Alvaro Lucioni
ULUna J. Lee
Una J. Lee
To identify demographic and clinical characteristics of patients with symptomatic pelvic floor mesh complications who underwent mesh removal at our academic medical center. The secondary goal was to determine patient-reported outcomes after mesh removal. We conducted a retrospective review of consecutive patients from 2011-2016 undergoing removal of mesh graft for treatment of symptomatic mesh-related complications. Patient demographics, comorbidities, symptoms, and mesh factors were evaluated. Outcomes after explant were determined by the Patient Global Impression of Improvement and a Likert satisfaction scale. One hundred fifty-six symptomatic patients underwent complete or partial pelvic floor mesh removal during the study period. Mid-urethral slings comprised 86% of explanted mesh grafts. Mesh exposure or erosion was identified in 72% of patients. Eighty-one percent of patients presented with pain, and 35% reported pain in the absence of exposure or erosion. Pre-operative comorbidities included psychiatric disease (54.5%), chronic pain (34.0%), irritable bowel syndrome (20.5%) and fibromyalgia (9.6%). Forty-three percent of patients reported current or past tobacco use. At mean follow-up of 14 months, 68% of responding patients reported improvement on the Patient Global Impression of Improvement after surgery. This research identified tobacco use, and psychiatric, immunosuppressive, and chronic pain conditions as prevalent in this cohort of patients undergoing mesh removal. Surgical removal can improve presenting symptoms, including for patients with pain in the absence of other indications.

20 September 2023 in World Neurosurgery
Verified
Journal Article
Closed access
SBScott Boop
Scott Boop
AGAlec Gibson
Alec Gibson
KPKyle Pedersen
Kyle Pedersen
DCDavid Coppel
David Coppel
SDSharon Durfy
Sharon Durfy
ARAli Ravanpay
Ali Ravanpay